Global Toxic Epidermal Necrolysis Market, By Symptoms (Fever, Body Aches, Red, Stinging Yes, Difficulty Swallowing, Runny Nose, Coughing, Sore Throat), Diagnosis (Physical Exam, Medical History, Skin Biopsy, Blood Test, Cultures), Treatment (Hospitalization, Ointments and Bandages, Intravenous (IV) Fluid and Electrolytes, Isolation) – Industry Trends and Forecast to 2030.
Toxic Epidermal Necrolysis Market Analysis and Size
Toxic epidermal necrolysis (TEN) is a rare, life-threatening drug-induced skin disease that has a 30% mortality rate. A prominent skin detachment caused by extensive keratinocyte cell death associated with mucosal involvement is the clinical hallmark of TEN. The precise pathogenic mechanism of TEN is unknown. Recent advances in this field have resulted in the identification of several factors that may contribute to the induction of keratinocyte apoptosis. Furthermore, specific human leukocyte antigen types appear to be linked to certain drugs and the development of TEN.
Data Bridge Market Research analyses that the toxic epidermal necrolysis market which was USD 7.6 billion in 2022, is expected to reach USD 10.40 billion by 2030, at a CAGR of 4% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Toxic Epidermal Necrolysis Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Symptoms (Fever, Body Aches, Red, Stinging Yes, Difficulty Swallowing, Runny Nose, Coughing, Sore Throat), Diagnosis (Physical Exam, Medical History, Skin Biopsy, Blood Test, Cultures), Treatment (Hospitalization, Ointments and Bandages, Intravenous (IV) Fluid and Electrolytes, Isolation)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Mölnlycke Health Care AB (Sweden), maxill inc. (Canada), Cadila Pharmaceuticals (India), BD (U.S.), Schulke India Pvt. Ltd. (India), Smith+Nephew (U.K.), Basic Pharma Life Science Pvt Ltd. (India), PSK Pharma Pvt.Ltd (India), Avrio Health L.P. (U.S.), 3M (U.S.), Biesterfeld AG (Germany), Vesimin Health (Spain) and Mylan N.V. (Spain)
|
|
Market Opportunities
|
|
Market Definition
Toxic epidermal necrolysis (TEN) is a rare and severe skin disease. It is sometimes caused by a negative drug reaction, such as anticonvulsants and antibiotics. The primary symptom is rapid peeling, which results in large, raw areas that can ooze or weep.
Global Toxic Epidermal Necrolysis Market Dynamics
Drivers
- Usage of Toxic Epidermal Necrolysis
The primary treatment for TEN is supportive care until the affected skin has re-epithelialized. Fluid resuscitation, pain management, wound care, and nutritional support are examples of supportive measures. The emergency department should prioritise two things in these cases: discontinuation of the offending drug and early referral to a burn unit or intensive care unit with experience in dealing with such cases. These two measures, when taken within the first 24 hours of blister formation, reduce infection rates, hospital stays, and improve overall survival.
Opportunities
- Usage of antibiotics
Antibiotics are expected to contribute significantly to growth in the toxic epidermal necrolysis market during the forecast period. Antibiotics are prescribed to the majority of patients suffering from toxic epidermal neurolysis in order to prevent or treat infections. On the other hand, immunoglobulins, are expected to contribute significantly to growth in the toxic epidermal necrolysis market during the forecast period.
Restraints/Challenges
The disorder can be caused by a drug reaction often antibiotics or anticonvulsive which may hamper the growth of the toxic epidermal necrolysis market in the above mentioned period.
This toxic epidermal necrolysis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the toxic epidermal necrolysis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Toxic Epidermal Necrolysis Market Scope
The toxic epidermal necrolysis market is segmented on the basis of symptoms, diagnosis and treatment. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Symptoms
- Fever
- Body Aches
- Red
- Stinging Yes
- Difficulty Swallowing
- Runny Nose
- Coughing
- Sore Throat
Diagnosis
- Physical Exam
- Medical History
- Skin Biopsy
- Blood Test
- Cultures
Treatment
- Hospitalization
- Ointments and Bandages
- Intravenous (IV) Fluid and Electrolytes
- Isolation
Toxic Epidermal Necrolysis Market Regional Analysis/Insights
The toxic epidermal necrolysis market is analysed and market size insights and trends are provided by country, symptoms, diagnosis and treatment as referenced above.
The countries covered in the toxic epidermal necrolysis market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the toxic epidermal necrolysis market because of growing awareness among patients and rapidly growing population.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 due to changing lifestyle of people and rising per capita expenditure.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The toxic epidermal necrolysis market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for toxic epidermal necrolysis market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the toxic epidermal necrolysis market. The data is available for historic period 2011-2021.
Competitive Landscape and Toxic Epidermal Necrolysis Market Share Analysis
The toxic epidermal necrolysis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to toxic epidermal necrolysis market.
Some of the major players operating in the toxic epidermal necrolysis market are:
- Mölnlycke Health Care AB (Sweden)
- maxill inc. (Canada)
- Cadila Pharmaceuticals (India)
- BD (U.S.)
- Schulke India Pvt. Ltd. (India)
- Smith+Nephew (U.K.)
- Basic Pharma Life Science Pvt Ltd. (India)
- PSK Pharma Pvt.Ltd (India)
- Avrio Health L.P. (U.S.)
- 3M (U.S.)
- Biesterfeld AG (Germany)
- Vesimin Health (Spain)
- Mylan N.V. (Spain)
SKU-